Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;17(Suppl 1):S203-5.
doi: 10.4103/2230-8210.119572.

A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting

Debmalya Sanyal  1 , Soumava Gupta, Pratik Das
Affiliations

A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting

Debmalya Sanyal et al. Indian J Endocrinol Metab. 2013 Oct.

Abstract

New-onset diabetes after transplantation (NODAT) is frequently encountered after kidney transplant. In the present study, we retrospectively evaluated the safety and efficacy of linagliptin monotherapy in 21 renal transplant recipients in a real world setting. We found linagliptin monotherapy is effective for glycemic control in NODAT, even on glucocorticoids and standard dose of tacrolimus. There was no alteration of tacrolimus drug levels or estimated glomerular filtration rate (eGFR) and minimal side effects, including weight gain and hypoglycemia. Well-designed, powered randomized controlled of antiglycemic agents in NODAT are needed.

Keywords: Linagliptin; new-onset diabetes after transplantation; renal transplant.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No

References

    1. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, et al. Transplantation 2003. Vol. 75. Barcelona, Spain: 2003. Feb 19, International Expert Panel. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting; pp. SS3–24. - PubMed
    1. Sulanc E, Lane JT, Puumala SE, Groggel GC, Wrenshall LE, Stevens RB. New-onset diabetes after kidney transplantation: An application of 2003 international guidelines. Transplantation. 2005;80:945–52. - PubMed
    1. Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant. 2011;11:1376–81. - PubMed
    1. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38:667–78. - PubMed
    1. Graefe-Mody U, Friedrich C, Port A. Effect of renal impairment on the pharmacokineticsof the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011;13:939–46. - PubMed